2009年6月5日
Topiramate induced agranulocytosis
BMJ Case Reports
- ,
- ,
- 巻
- 2009
- 号
- 記述言語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1136/bcr.11.2008.1273
A man in his 40s with a past history of neutropenia during zonisamide administration developed agranulocytosis 1 month after adding on topiramate to treat intractable partial epilepsy. His concurrent medication included phenytoin and acetazolamide. His white blood cell count recovered 5 days after discontinuation of topiramate. Topiramate is a sulfamate whose mechanism of antiepileptic activity is considered to include inhibition of carbonic anhydrase. Topiramate has a potential risk for haematopoietic adverse events; such events are rare and are related to immuno-allergic reaction or toxic effect of sulf onamides and sulf amates, including carbonic anhydrase inhibitors. Because this class of drugs is commonly used as an anti-glaucoma or diuretic agent, particular attention should be paid when initiating topiramate to a patient with a history of sulfonamide or sulfamate induced agranulocytosis, or when co-administrating topiramate with sulf onamides and sulf amates including carbonic anhydrase inhibitors.
- リンク情報
- ID情報
-
- DOI : 10.1136/bcr.11.2008.1273
- eISSN : 1757-790X
- PubMed ID : 21686380
- SCOPUS ID : 84877884052